ASRS 2026: MCO-010 optogenetic therapy sustains 3-line vision gains at 3 years in retinitis ...

Written on 07/21/2026

... regardless of gene mutation, with no treatment-related serious adverse events, per Benjamin Bakall, MD, PhD, at ASRS 2026.